Celon Pharma SA (CLN) — Capital Reinvestment Ratio

Latest as of June 2025: 6.28x

Celon Pharma SA (CLN) has a Capital Reinvestment Ratio of 6.28x as of June 2025, meaning it reinvests 6% of its operating cash flow (zł3.51 Million) in capital expenditures (zł22.07 Million). See how leveraged is Celon Pharma SA's balance sheet to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

6.28x
Capex / Operating Cash Flow

Operating Cash Flow

zł3.51 Million
PLN

Capital Expenditures

zł22.07 Million
PLN

Data as of

Jun 2025
Most recent filing

Celon Pharma SA Capital Reinvestment Ratio (2012–2021)

This chart tracks Celon Pharma SA's Capital Reinvestment Ratio across 9 annual periods. Check CLN capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Celon Pharma SA (2012–2021)

Year-by-year Capital Reinvestment Ratio for Celon Pharma SA from 2012 to 2021. For live market cap and broader valuation context, see CLN market cap overview.

Year Reinvestment Ratio Operating CF (PLN) Capital Expenditures YoY Change
2021 0.94x zł43.95 Million zł41.35 Million ▼ -32.7%
2020 1.40x zł70.90 Million zł99.16 Million ▼ -41.5%
2018 2.39x zł28.24 Million zł67.46 Million ▲ +92.9%
2017 1.24x zł25.30 Million zł31.34 Million ▲ +20.1%
2016 1.03x zł20.65 Million zł21.29 Million ▲ +20.4%
2015 0.86x zł52.37 Million zł44.86 Million ▼ -7.5%
2014 0.93x zł24.36 Million zł22.55 Million ▲ +38.6%
2013 0.67x zł8.45 Million zł5.64 Million ▲ +97.8%
2012 0.34x zł12.87 Million zł4.34 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow